Beyond The Numbers: 7 Analysts Discuss Silence Therapeutics Stock
7 analysts have expressed a variety of opinions on Silence Therapeutics (NASDAQ:SLN) over the past quarter, offering a diverse set of opinions from bullish to bearish.The table below summarizes their
BenzingaApr 22 14:00 ET
Express News | Morgan Stanley Maintains Overweight on Silence Therapeutics, Maintains $45 Price Target
Moomoo 24/7Apr 22 13:29 ET
Silence Therapeutics Plc's (NASDAQ:SLN) Market Cap Touched US$1.1b Last Week, Benefiting Both Retail Investors Who Own 27% as Well as Institutions
Key Insights Silence Therapeutics' significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public 54% of the business is held by the top
Simply Wall StApr 22 08:01 ET
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down
European equities traded in the US as American depositary receipts were trending higher Friday morning, rising 0.46% to 1,330.20 on the S&P Europe Select ADR Index. Despite the gain, the index remains
MT NewswiresApr 19 11:10 ET
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading
European equities traded in the US as American depositary receipts were lower Tuesday morning, declining 0.67% to 1,332.69 on the S&P Europe Select ADR Index. From continental Europe, the gainers were
MT NewswiresApr 16 11:15 ET
Silence Therapeutics Announces Upcoming AGM
TipRanksApr 15 21:01 ET
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading
European equities traded in the US as American depositary receipts kicked off the week trending moderately higher Monday morning, rising 0.53% to 1,352.74 on the S&P Europe Select ADR Index. From cont
MT NewswiresApr 15 11:08 ET
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading
European equities traded in the US as American depositary receipts were lower Friday morning, falling 0.66% to 1,356.48 on the S&P Europe Select ADR Index. The index is poised to close the week down n
MT NewswiresApr 12 11:09 ET
Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects With Elevated Lipoprotein(a)
Published findings demonstrate zerlasiran was well-tolerated and significantly reduced Lp(a) after single and multiple dosingLONDON--(BUSINESS WIRE)--$SLN #SenseofSilence--Silence Therapeutics plc, Na
BusinesswireApr 8 11:48 ET
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday Trading
European equities traded in the US as American depositary receipts were trending slightly higher late Wednesday morning, rising 0.18% to 1,370.27 on the S&P Europe Select ADR Index. From continental E
MT NewswiresMar 27 11:11 ET
European Equities Traded in the US as American Depositary Receipts Start Week Slightly Lower in Monday Trading
European equities traded in the US as American depositary receipts opened the week modestly lower Monday morning, declining 0.23% to 1,353.40 on the S&P Europe Select ADR Index. From continental Europ
MT NewswiresMar 18 11:15 ET
Analysts Are Upgrading Silence Therapeutics Plc (NASDAQ:SLN) After Its Latest Results
Yahoo FinanceMar 16 08:29 ET
Express News | HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target
Moomoo 24/7Mar 15 12:57 ET
Silence Therapeutics Plc (NASDAQ:SLN) Q4 2023 Earnings Call Transcript
Yahoo FinanceMar 15 11:56 ET
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Friday Trading
European equities traded in the US as American depositary receipts were slightly lower Friday morning, falling 0.19% to 1,359.70 on the S&P Europe Select ADR Index. Despite the decline, the index is s
MT NewswiresMar 15 11:10 ET
These Analysts Boost Their Forecasts On Silence Therapeutics After Full Year 2023 Results
Silence Therapeutics Plc (NASDAQ:SLN) reported a loss for 2023 on Wednesday. The company reported a loss per share of (38.9) pence for 2023, narrower than the (41.9) pence loss per share a year ago, a
BenzingaMar 14 14:01 ET
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading
European equities traded in the US as American depositary receipts were tracking moderately lower Thursday morning, falling 0.75% to 1,362.82 on the S&P Europe Select ADR Index. From continental Europ
MT NewswiresMar 14 11:14 ET
Silence Therapeutics Is Maintained at Buy by Chardan Capital
Silence Therapeutics Is Maintained at Buy by Chardan Capital
Dow JonesMar 14 08:05 ET
Morgan Stanley Boosts Price Target on Silence Therapeutics to $45 From $29, Says Q4 Showed 'Meaningful Progress,' Keeps Overweight Rating
Silence Therapeutics (SLN) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $42 to $75.
MT NewswiresMar 14 07:57 ET
Express News | Chardan Capital Maintains Buy on Silence Therapeutics, Raises Price Target to $42
Moomoo 24/7Mar 14 07:54 ET
No Data
No Data